VAXCYTE, INC. (PCVX) Free cash flow
- Free cash flow · 12 months (USD): Value $-894.14M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-894.14M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-881.23M − $12.90M ≈ $-894.14M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-881.23M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 2.95× | Operating cash flow / net income. Period ending 2026-06-30. $-881.23M ÷ $-298.40M ≈ 2.95× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -881.23M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 12.90M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -894.14M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -298.40M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-894.14M | (m) | $-881.23M | $12.90M | (m) | (m) | (m) | $-298.40M | (m) | (m) | (m) | 2.95× |
| 2026-03-31 | $-780.32M | (m) | $-769.93M | $10.40M | (m) | (m) | (m) | $-180.67M | (m) | (m) | (m) | 4.26× |
| 2025-12-31 | $-669.29M | (m) | $-655.58M | $13.71M | (m) | (m) | (m) | $-766.63M | (m) | (m) | (m) | 0.86× |
| 2025-09-30 | $-557.23M | (m) | $-542.15M | $15.08M | (m) | (m) | (m) | $-657.20M | (m) | (m) | (m) | 0.82× |
| 2025-06-30 | $-475.75M | (m) | $-459.55M | $16.20M | (m) | (m) | (m) | $-547.50M | (m) | (m) | (m) | 0.84× |
| 2025-03-31 | $-481.95M | (m) | $-459.78M | $22.17M | (m) | (m) | (m) | $-509.63M | (m) | (m) | (m) | 0.90× |
| 2024-12-31 | $-475.05M | (m) | $-452.63M | $22.43M | (m) | (m) | (m) | $-463.93M | (m) | (m) | (m) | 0.98× |
| 2024-09-30 | $-493.70M | (m) | $-470.04M | $23.66M | (m) | (m) | (m) | $-507.65M | (m) | (m) | (m) | 0.93× |
| 2024-06-30 | $-492.93M | (m) | $-466.88M | $26.05M | (m) | (m) | (m) | $-497.19M | (m) | (m) | (m) | 0.94× |
| 2024-03-31 | $-424.36M | (m) | $-408.22M | $16.13M | (m) | (m) | (m) | $-436.82M | (m) | (m) | (m) | 0.93× |
| 2023-12-31 | $-312.85M | (m) | $-296.79M | $16.06M | (m) | (m) | (m) | $-402.27M | (m) | (m) | (m) | 0.74× |
| 2023-09-30 | $-245.16M | (m) | $-233.20M | $11.96M | (m) | (m) | (m) | $-299.51M | (m) | (m) | (m) | 0.78× |
| 2023-06-30 | $-219.66M | (m) | $-214.20M | $5.46M | (m) | (m) | (m) | $-264.77M | (m) | (m) | (m) | 0.81× |
| 2023-03-31 | $-199.12M | (m) | $-190.59M | $8.54M | (m) | (m) | (m) | $-244.96M | (m) | (m) | (m) | 0.78× |
| 2022-12-31 | $-176.44M | (m) | $-170.60M | $5.85M | (m) | (m) | (m) | $-223.49M | (m) | (m) | (m) | 0.76× |
| 2022-09-30 | $-162.55M | (m) | $-156.47M | $6.08M | (m) | (m) | (m) | $-174.00M | (m) | (m) | (m) | 0.90× |
| 2022-06-30 | $-153.29M | (m) | $-146.34M | $6.96M | (m) | (m) | (m) | $-142.70M | (m) | (m) | (m) | 1.03× |
| 2022-03-31 | $-144.12M | (m) | $-135.89M | $8.23M | (m) | (m) | (m) | $-117.84M | (m) | (m) | (m) | 1.15× |
| 2021-12-31 | $-127.95M | (m) | $-121.39M | $6.55M | (m) | (m) | (m) | $-100.08M | (m) | (m) | (m) | 1.21× |
| 2021-09-30 | $-86.96M | (m) | $-81.07M | $5.89M | (m) | (m) | (m) | $-92.25M | (m) | (m) | (m) | 0.88× |
| 2021-06-30 | $-69.91M | (m) | $-65.71M | $4.21M | (m) | (m) | (m) | $-86.65M | (m) | (m) | (m) | 0.76× |
| 2021-03-31 | $-48.25M | (m) | $-46.20M | $2.05M | (m) | (m) | (m) | $-83.30M | (m) | (m) | (m) | 0.55× |
| 2020-12-31 | $-47.78M | (m) | $-46.63M | $1.16M | (m) | (m) | (m) | $-89.22M | (m) | (m) | (m) | 0.52× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-63.74M | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-48.34M | (m) | $-47.15M | $1.20M | (m) | (m) | (m) | $-50.27M | (m) | (m) | (m) | 0.94× |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-32.24M | (m) | $-30.47M | $1.77M | (m) | (m) | (m) | $-29.48M | (m) | (m) | (m) | 1.03× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |